mRNA technology discovery and development company, eTheRNA immunotherapies has announced it has relocated its R&D group to a larger site in Belgium.
The company has moved its R&D facility to the Zwijnaarde Science Park in Gent, Belgium, which features a cluster of biotech companies and includes laboratories and allied services. The move has been made to increase eTheRNA’s R&D capacity and enable its research departments to enhance their investigations on a variety of mRNA and lipid nanoparticles for R&D applications. The company hopes that this will result in improved control and faster production cycles.
Stefaan De Koker, eTheRNA VP of Discovery, said: “We are excited that this move gives us the opportunity to upgrade our R&D facility, allowing us to expand our activities and accomplish the ambitious goals that we have set for our research and development programs. This new facility makes it possible for us to strengthen our capabilities across the board, and we intend to leverage it fully to achieve our company milestones.”